0001683168-18-000770.txt : 20180328
0001683168-18-000770.hdr.sgml : 20180328
20180328080110
ACCESSION NUMBER: 0001683168-18-000770
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170714
FILED AS OF DATE: 20180328
DATE AS OF CHANGE: 20180328
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dowling Joseph D
CENTRAL INDEX KEY: 0001611860
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-54677
FILM NUMBER: 18717043
MAIL ADDRESS:
STREET 1: 591 CAMINO DE LA REINA, STE 1200
CITY: SAN DIEGO
STATE: CA
ZIP: 92108
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CV Sciences, Inc.
CENTRAL INDEX KEY: 0001510964
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 800944970
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2688 SOUTH RAINBOW AVENUE, SUITE B
CITY: LAS VEGAS
STATE: NV
ZIP: 89146
BUSINESS PHONE: 866-290-2157
MAIL ADDRESS:
STREET 1: 2688 SOUTH RAINBOW AVENUE, SUITE B
CITY: LAS VEGAS
STATE: NV
ZIP: 89146
FORMER COMPANY:
FORMER CONFORMED NAME: CannaVEST Corp.
DATE OF NAME CHANGE: 20130205
FORMER COMPANY:
FORMER CONFORMED NAME: Foreclosure Solutions, Inc.
DATE OF NAME CHANGE: 20110124
4
1
dowling_f4.xml
OWNERSHIP DOCUMENT
X0306
4
2017-07-14
0
0001510964
CV Sciences, Inc.
CVSI
0001611860
Dowling Joseph D
2688 S. RAINBOW BLVD., SUITE B
LAS VEGAS
NV
89146
0
1
0
0
CFO, Secretary
Employee Stock Option (right to buy)
0.368
2017-07-14
4
A
0
250000
0
A
2017-07-14
2026-07-05
Common Stock
250000
250000
D
Employee Stock Option (right to buy)
0.365
2017-07-14
4
A
0
250000
0
A
2017-07-14
2027-04-06
Common Stock
250000
250000
D
On July 6, 2016, the Reporting Person was granted an option to purchase 1,000,000 shares of the Issuer's Common Stock. The option is performance-based, and vests and becomes exercisable as follows: (i) the first time the Issuer completes development of a U.S. Food & Drug Administration ("FDA") current good manufacturing practice grade batch of successfully synthetically formulated Cannabidiol ("CBD") for use in drug development activities (25% vesting of the shares subject to the option); (ii) when the Company has final meeting minutes from a pre-investigational new drug application ("IND") meeting as authorized by the FDA for a drug development program utilizing CBD as the active pharmaceutical ingredient (25% vesting of the shares subject to the option); (iii) when the Company is granted an IND (25% vesting of the shares subject to the option); and (iv) when the Company commences its first human dosing under the IND (25% vesting of the shares subject to the option).
On July 14, 2017, the second performance criterion was met resulting in vesting of the option as to 250,000 shares.
On April 7, 2017, the Reporting Person was granted an option to purchase 1,000,000 shares of the Issuer's Common Stock. The option is performance-based, and vests and becomes exercisable as follows: (i) when the Company has final meeting minutes from a pre-IND meeting as authorized by the FDA for a drug development program utilizing CBD as the active pharmaceutical ingredient (25% vesting of the shares subject to the option); (ii) when the Company is granted an IND (25% vesting of the shares subject to the option); and (iii) when the Company commences its first human dosing under the IND (50% vesting of the shares subject to the option). On July 14, 2017, the first performance criterion was met resulting in vesting of the option as to 250,000 shares.
/s/ Joseph Dowling
2018-03-27